Table 2.
Summary of cHCC-CCA CLs
| Primary Tumor | Morphology | Doubling Time(h) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient age | Gender | Tumor site | HBV | AFP | CEA | CA19-9 | ||||
| CHC-X1 | 31 | Male | Left liver | negative | 9.3U/ml | 943ng/ml | normal | polygon | 50.72 | |
| KMCH-1 | 52 | Male | Left liver | negative | normal | 4.2ng/ml | -- | oval | 39 | |
| KMCH-2 | 40 | Male | Right liver | negative | 29ng/ml | 2.3ng/ml | 317U/ml | polygon |
44 (P20) 32 (P55) |
|
| IC 50 | Tumor Markers | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Oxaliplatin | Gemcitabine | 5-FU | Paclitaxel | CK7 | CK19 | AFP | Glypican3 | Arginase1 | Albumin | |
| CHC-X1 | 9.907μmol/L | 13.22μmol/L | 123.9μmol/L | 0.03107μmol/L | positive | positive | positive | positive | positive | positive |
| KMCH-1 | -- | 0.0089μmol/L | -- | >1μmol/L | positive | positive | -- | -- | -- | -- |
| KMCH-2 | -- | -- | -- | -- | -- | positive | -- | -- | -- | positive |